| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | S-Trityl-L-cysteine | FIMM | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | palmostatin B | CTRPv2 | pan-cancer | AAC | -0.0028 | 1 |
| mRNA | Mdivi-1 | CTRPv2 | pan-cancer | AAC | 0.0022 | 1 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | -0.0032 | 1 |
| mRNA | XMD8-92 | GDSC1000 | pan-cancer | AAC | -0.0021 | 1 |